Avacta's FAP-EXd Candidate Demonstrates Strong Preclinical Efficacy

PUBLISHED: 28 Apr 2025 @ 18:21 | Comments (0) | More info about Fiona Craig

Avacta Group PLC (LSE:AVCT) has unveiled encouraging preclinical results for its second pre|CISION® candidate, FAP-EXd (AVA6103), at the AACR Annual Meeting. The candidate showcased significant inhibition of tumor growth and achieved complete responses in models resistant to existing therapies. These results underscore the potential of Avacta’s proprietary platform to deliver targeted cancer treatments with minimal systemic toxicity. The pre|CISION® platform works by targeting fibroblast activation protein (FAP), which is overexpressed in solid tumors, enabling the precise delivery of potent drugs such as exatecan directly to tumor sites. The data reinforces the platform’s capability to revolutionize cancer treatment and provide long-term value for stakeholders.

About Avacta Group PLC

Avacta Group is a clinical-stage life sciences company focused on the development of innovative cancer therapies using its proprietary pre|CISION® platform. The platform targets the tumor-specific protease fibroblast activation protein (FAP), enabling highly concentrated therapeutic agents to act within the tumor microenvironment while minimizing damage to healthy tissues. Avacta’s pipeline includes peptide drug conjugates (PDCs) and Affimer® drug conjugates (AffDCs), offering a promising alternative to traditional antibody-drug conjugates.

Year-to-Date Price Change: -37.00%
Average Daily Trading Volume: 1,861,978 shares
Technical Sentiment Indicator: Buy
Current Market Capitalization: £120.8 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.